Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1497504/000143774919004386/plxp20181231_10k.htm
SEC Filings
PLXP Annual Reports
PLXP Quarterly Reports
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report November 2022
10-Q Quarterly Report August 2022
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
PLXP Corporate News
Event for Officers
Financial Exhibit
Other Events March 2023
Event for Officers
Financial Exhibit
Listing Status February 2023
Event for Officers
Financial Exhibit
Other Events January 2023
Earnings Release
Event for Officers
Financial Exhibit
Vote of Security Holders November 2022
Financial Exhibit
Listing Status October 2022
Earnings Release
Financial Exhibit
Other Events August 2022
Earnings Release
Financial Exhibit May 2022
Bylaw Change
Financial Exhibit April 2022
Financial Exhibit
Regulated Disclosure March 2022
Earnings Release
Financial Exhibit March 2022
Event for Officers
Financial Exhibit
Other Events
Financial Exhibit
Other Events
March 2023
Event for Officers
Financial Exhibit
Listing Status
Financial Exhibit
Listing Status
February 2023
Event for Officers
Financial Exhibit
Other Events
Financial Exhibit
Other Events
January 2023
Earnings Release
Event for Officers
Financial Exhibit
Vote of Security Holders
Event for Officers
Financial Exhibit
Vote of Security Holders
November 2022
Financial Exhibit
Listing Status
Listing Status
October 2022
Earnings Release
Financial Exhibit
Other Events
Financial Exhibit
Other Events
August 2022
Earnings Release
Financial Exhibit
Financial Exhibit
May 2022
Bylaw Change
Financial Exhibit
Financial Exhibit
April 2022
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
March 2022
Earnings Release
Financial Exhibit
Financial Exhibit
March 2022
Last10K.com | 10-K Annual Report Fri Mar 08 2019
Document And Entity Information - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2018 | Mar. 01, 2019 | Jun. 29, 2018 | |
| Document Information [Line Items] | |||
| Entity Registrant Name | PLx Pharma Inc. | ||
| Entity Central Index Key | 0001497504 | ||
| Trading Symbol | plxp | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Emerging Growth Company | true | ||
| Entity Small Business | true | ||
| Entity Common Stock, Shares Outstanding (in shares) | 8,750,606 | ||
| Entity Public Float | $ 34,053,848 | ||
| Document Type | 10-K | ||
| Document Period End Date | Dec. 31, 2018 | ||
| Document Fiscal Year Focus | 2018 | ||
| Document Fiscal Period Focus | FY | ||
| Amendment Flag | false | ||
| Entity Shell Company | false | ||
| Entity Ex Transition Period | true |
View differences made from one year to another to evaluate Plx Pharma Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Plx Pharma Inc..
Assess how Plx Pharma Inc.'s management team is paid from their Annual Proxy
Plx Pharma Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Other - Other Highlight
A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations.
-
Other - Other Highlight
Specifically, critical accounting estimates have the following attributes: (1) we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and (2) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.
-
Financial - Expense Highlight
We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we continue the development and commercialization of Vazalore and our other product candidates.
-
Financial - Shares Highlight
Net cash provided by financing activities in 2017 consisted of approximately $16.7 million of equity offering proceeds, $2.0 million pursuant to the note issued to Dipexium prior to the Merger, $7.1 million in net proceeds under a term loan from Silicon Valley Bank, and approximately $0.6 million of proceeds pursuant to a convertible note which subsequently converted to Old PLx equity immediately prior to the closing of the Merger.
-
Revenue - Product Highlight
Given our clinical demonstration of better antiplatelet efficacy (as compared with enteric-coated aspirin) and better GI safety, we intend to use a physician-directed sales force to inform physicians - and, by extension, consumers - about our products clinical results in an effort to command both greater market share and a higher price for our next generation aspirin product.
-
Revenue - Product
All the revenue recognized in...Read more
-
Financial - Expense
General and Administrative Expenses General...Read more
-
Other - Other
Inflation The Company believes that...Read more
-
Other - Other
Because of the Company?s existing...Read more
-
Other - Other
We are a late-stage specialty...Read more
-
Revenue - Product
We believe the following critical...Read more
-
Other - Other
Net Cash Provided by Investing...Read more
-
Financial - Expense
Operating expenses for the years...Read more
-
Financial - Income
Other income (expense), net Other...Read more
-
Other - Other
Additional financing may not be...Read more
-
Financial - Income
The Company adopted new accounting...Read more
-
Revenue - Product
Even if we do generate...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statement Of Changes In Stockholders' Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Note 1 - Background And Organization
Note 1 - Background And Organization (Details Textual)
Note 10 - Income Taxes
Note 10 - Income Taxes (Details Textual)
Note 10 - Income Taxes (Tables)
Note 10 - Income Taxes - Income Tax (Expense) Benefit (Details)
Note 10 - Income Taxes - Income Tax Rate Reconciliation (Details)
Note 10 - Income Taxes - Significant Components Of The Deferred Tax Assets And Liabilities (Details)
Note 11 - Subsequent Event
Note 11 - Subsequent Event (Details Textual)
Note 2 - Liquidity And Going Concern
Note 3 - Summary Of Significant Accounting Policies
Note 3 - Summary Of Significant Accounting Policies (Details Textual)
Note 4 - Reverse Merger Business Combination
Note 4 - Reverse Merger Business Combination (Details Textual)
Note 4 - Reverse Merger Business Combination (Tables)
Note 4 - Reverse Merger Business Combination - Allocation Of Estimated Purchase Consideration (Details)
Note 4 - Reverse Merger Business Combination - Purchase Consideration (Details)
Note 4 - Reverse Merger Business Combination - Unaudited Pro Forma Results (Details)
Note 5 - Long-Lived Assets
Note 5 - Long-Lived Assets (Details Textual)
Note 5 - Long-Lived Assets (Tables)
Note 5 - Long-Lived Assets - Goodwill And Intangible Assets (Details)
Note 5 - Long-Lived Assets - Property And Equipment (Details)
Note 6 - Debt
Note 6 - Debt (Details Textual)
Note 7 - Stockholders Equity - Stock Option Activity (Details)
Note 7 - Stockholders' Equity
Note 7 - Stockholders' Equity (Details Textual)
Note 7 - Stockholders' Equity (Tables)
Note 8 - Commitments And Contingencies
Note 8 - Commitments And Contingencies (Details Textual)
Note 8 - Commitments And Contingencies (Tables)
Note 8 - Commitments And Contingencies - Future Minimum Obligations And Sublease Income (Details)
Note 9 - Fair Value Measurements
Note 9 - Fair Value Measurements (Details Textual)
Note 9 - Fair Value Measurements (Tables)
Note 9 - Fair Value Measurements - Carrying Amount Of Assets And Liabilities (Details)
Note 9 - Fair Value Measurements - Measured At Fair Value On A Recurring Basis (Details)
Significant Accounting Policies (Policies)
Material Contracts, Statements, Certifications & more
Plx Pharma Inc. provided additional information to their SEC Filing as exhibits
Exhibit 10.18: Material Contract
Exhibit 10.19: Material Contract
Exhibit 10.20: Material Contract
Exhibit 10.21: Material Contract
Exhibit 10.22: Material Contract
Exhibit 21.1: Subsidaries Of The Registrant
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 23.2: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: PLXP
CIK: 1497504
Form Type: 10-K Annual Report
Accession Number: 0001437749-19-004386
Submitted to the SEC: Fri Mar 08 2019 2:32:31 AM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/plxp/0001437749-19-004386.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...